Mechanism of Action: Cytochrome P450 2C8 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Cytochrome P450 2C8 Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-001 | Apr 28, 2011 | AB | RX | Yes | No | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | |||
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-002 | Apr 14, 2017 | AB | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | |||
Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-002 | Nov 20, 2020 | RX | Yes | Yes | 7,838,531 | ⤷ Try for Free | ⤷ Try for Free | ||||
Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-002 | Nov 20, 2020 | RX | Yes | Yes | 8,828,356 | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |